Jessica Mercer, MD, serves as co-managing owner of Georgia Dermatology Partners near Atlanta, Georgia.

, Andrew Alexis, MD, MPH, professor of clinical dermatology at Weill Cornell Medicine in New York City, spoke about how mentorship shaped his own career and continues to influence the next generation of dermatologists, in a segment of his conversation with host Jessica Mercer, MD, co-managing owner of Georgia Dermatology Partners near Atlanta, Georgia.

Why Mentorship Matters Most for Dermatology Trainees

Alexis said looking back on his career made clear that no physician reaches success alone, crediting the support, guidance, and inspiration of his own mentors while expressing gratitude for the chance to pass those lessons on to students and residents, including Mercer, who trained and shadowed under him earlier in her career.

How Does Mentorship Shape a Physician's Clinical Focus?

Mercer credited Alexis, along with Susan Taylor, MD, who led the Skin of Color Center in New York, with laying the foundation for her current focus on hair loss and skin of color care. Alexis explained that exposure to varied clinical approaches during mentorship often sparks lasting interest in a specific subspecialty, noting that for many trainees, mentorship offers a first meaningful exposure to conditions prevalent in skin of color.

Why Is Mentorship Especially Important for Dermatology Trainees?

Mercer noted that trainees practicing in different regions may have limited exposure to certain patient populations and conditions depending on where they train, making mentorship a critical supplement to formal education. Alexis agreed, explaining that observing experienced clinicians model varying approaches allows trainees to build a broader toolkit they can later draw from in their own practice, often blending techniques learned from multiple mentors and clinical settings.

Mercer said she now applies this understanding in her own mentorship relationships, making a point to ask trainees what they hope to gain from the experience, since different mentees often need different forms of guidance and support.

To learn more about SOCS’s programs and initiatives, visit 

Editor’s note: This episode was summarized with the help of AI tools. Alexis and Mercer had no relevant disclosures of note.

Perlman KL, Williams NM, Park JH, et al. Skin of color lacks representation in medical student resources: A cross-sectional study. Int J Womens Dermatol. 2021 Jan 8;7(2):195-196. 

Videos

Andrew Alexis, MD, MPH, and Jessica Mercer, MD, discuss how mentorship shapes dermatology careers and supplements trainee education.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Donald Lloyd-Jones, MD, MS | Image Credit: Northwestern University

Almost 8 in 10 young adults in their early 20s have 

cardiovascular-kidney-metabolic (CKM) syndrome

 – and patients with more advanced CKM showed more signs of arterial damage, according to new data from the American Heart Association.

CKM syndrome describes the relationship between 

, and cardiovascular disease. Recently released clinical guidelines have developed a categorization system in which different stages reflect a person’s risk factors. These stages range from Stage 0 (no risk factors) to 4 (existing cardiovascular conditions like coronary heart disease, stroke, or heart failure).

“The study shows that CKM syndrome staging and Life’s Essential 8 are complementary for identifying adults younger than age 30 who may be on the fast track for arterial injury, plaque build-up and, ultimately, at higher risk for future cardiovascular events,” Donald Lloyd-Jones, MD, MS, a cardiologist at Boston Medical Center, professor of medicine at Boston University’s Chobanian & Avedisian School of Medicine, director of the Framingham Center for Population and Prevention Science, and lead author of the study, said in a statement.

The study, titled Future of Families-Cardiovascular Health Among Young Adults (FF-CHAYA), was an ancillary study of the Future of Families and Child Well-Being Study (FFCWS). The latter enrolled roughly 5000 mother-baby dyads at birth between 1998 and 2000, with an oversampling of unmarried mothers. FFCWS conducted 7 waves of data collection at birth and roughly ages 1, 3, 5, 9, 15, and 22 of the children. The FF-CHAYA substudy involved an in-person examination after completing year 22 of FFCWS.

The in-person examination consisted of objective assessments of blood pressure and anthropometric measures, as well as phlebotomy for lab analyses of blood lipids, hemoglobin A1c, and serum creatinine, and carotid ultrasonography. Patients also completed self-administered questionnaires regarding medical history and medication usage, as well as standardized questionnaires to assess diet, physical activity, sleep, and nicotine exposure.

Lloyd-Jones and colleagues used the staging construct from the American Heart Association to assign each participant to a CKM stage between 0 and 3. Stage 0 CKM represents no risk factors, stage 1 CKM represents excess or dysfunctional adiposity, Stage 2 represents metabolic or kidney risk factors, and Stage 3 represents subclinical cardiovascular disease or high-risk equivalents. Stage 4 CKM was not included in the analysis, as patients meeting criteria for clinical cardiovascular disease were excluded from the study.

The 1283 patients who were included in the final sample had a mean age of 22.9 years (standard deviation [SD] 0.7), and 54.4% were women. Of these patients, Lloyd-Jones and colleagues classified 20.7% at Stage 0, 40.2% at Stage 1, 36.2% at Stage 2, and 2.8% at Stage 3, indicating a significant burden of excess adiposity, medical risk factors, and subclinical cardiovascular disease, respectively.

Mean Life’s Essential 8 scores were also calculated for each patient – among the full FF-CHAYA patient group, mean cardiovascular health score was 69.2 (95% CI, 68.4-69.9). Overall scores differed by CKM stage, from 77.6 (95% CI, 76.1-79.1) in Stage 0 to 64.4 (95% CI, 60.5-68.4) in Stage 3 (

 <.01). While mean health behaviors-only scores and individual health behavior metrics did not significantly differ across stages, mean dietary quality and physical activity scores were low.

Carotid ultrasonography revealed that mean-mean common carotid intima-medial thickness (cIMT) was 0.504 mm (0.501-0.507), while mean-maximum cIMT was 0.641 mm (0.637-0.644) and gray scale median was 77.3 (76.5-78.1). More advanced CKM stage saw both mean-mean and mean-maximum cIMT increase substantially, while gray scale median was significantly lower.

Lloyd-Jones and colleagues did note a few limitations to the study, including its cross-sectional design’s inability to establish cause and effect and the study population’s inclusion primarily of patients from disadvantaged backgrounds. This may reduce the generalizability of the data. However, the team concluded that these findings still represent an urgent need for prevention efforts earlier in life.

“In my practice, and what I would recommend, is that the conversation focuses on Life’s Essential 8 and optimizing as many of those metrics as possible for better heart health today and long-term,” Lloyd-Jones said in a statement. “For people in their 20s, we want to focus on improving cardiovascular health.”

American Heart Association. Study found artery damage in adults in their 20s, highlighting need for early cardiovascular risk assessment. 

 August 20, 2026. Accessed August 20, 2026. 

https://www.eurekalert.org/news-releases/1140275

Krishnan V, Ning H, Notterman DA, et al. Association between cardiovascular-kidney-metabolic health and early arterial injury in young adults in the United States: The future of families–cardiovascular health among young adults study. 

. August 20, 2026. Accessed August 20, 2026. 

Articles

Nearly 80% of U.S. young adults around age 23 met criteria for cardiovascular-kidney-metabolic (CKM) syndrome stages 1–3, with higher stages associated with early arterial injury. In the FF-CHAYA examination cohort (n=1,283), CKM staging tracked stepwise declines in Life’s Essential 8 cardiovascular health scores and adverse carotid ultrasound phenotypes. Mean dietary quality and physical activity were uniformly low across stages. Findings underscore substantial subclinical risk accumulation by the early 20s and support earlier, metric-driven primordial prevention.

A new study from the AHA has indicated the real prevalence of CKM syndrome stages 0-3 in young adults in their 20s.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Chronic Kidney Disease

Type 2 Diabetes

CKM Syndrome, Artery Damage Prevalence Higher in Young Adults than Previously Believed

A year after the US Food & Drug Administration approved brensocatib (Brinsupri) as the first disease-modifying therapy for non-cystic fibrosis bronchiectasis, pulmonologists are refining which patients benefit most while reporting a tolerability profile that has not deterred uptake.

The FDA approved brensocatib for non-cystic fibrosis bronchiectasis on August 12, 2025. The decision was based on the phase 3 ASPEN trial, which enrolled > 1700 patients and showed both the 10 mg and 25 mg doses of brensocatib reduced annualized exacerbation rates by 20% compared with placebo. The 25 mg dose also showed lung function decline over 12 months.¹

bensocatib Patient Selection Evolves 1 Year After FDA Approval

Bensocatib Patient Selection Evolves 1 Year After FDA Approval

Mark L. Metersky, MD, FCCP, FACP, professor of medicine and director of the Center for Bronchiectasis Care at UConn Health, has prescribed brensocatib since its approval and shared his approach to patient selection and tolerability in an interview with 

"Bronchiectasis is quite heterogeneous, so it's likely not every patient will benefit," Metersky said. "For me, what I'm doing is using it in patients who have frequent exacerbations."

Brensocatib Patient Selection and ASPEN Trial Data

The ASPEN trial randomized patients with non-cystic fibrosis bronchiectasis to 10 mg brensocatib, 25 mg brensocatib, or placebo for 52 weeks across international sites. Both doses met the primary endpoint of a reduced annualized exacerbation rate compared with placebo, and the 25 mg dose additionally slowed the rate of forced expiratory volume in 1 second (FEV1) decline.¹

Metersky said patients with a high daily symptom burden, such as frequent cough with copious purulent sputum despite an absence of frequent exacerbations, may also derive benefit based on the drug's mechanism of action and the pattern of trial results. He added patients with rapidly declining lung function are additional potential candidates, given the 25 mg dose's demonstrated effect on FEV1 decline, though data specific to this subgroup remain unavailable.

Brensocatib Safety Profile and Patient Tolerability

Brensocatib (Brinsupri) is approved by the FDA as a disease-modifying therapy for non-cystic fibrosis bronchiectasis in patients 12 years and older, based on results from the phase 3 ASPEN trial.

Brensocatib is an oral, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), an enzyme responsible for activating neutrophil serine proteases implicated in bronchiectasis airway inflammation.

Which bronchiectasis patients are most likely to benefit from brensocatib? 

Metersky prioritizes patients with frequent exacerbations, the population studied in ASPEN, and considers patients with a high daily symptom burden or rapidly declining lung function additional potential candidates, though these groups were not directly studied in the trial.

The most common adverse events in ASPEN were consistent with the safety profile observed in earlier studies, and the phase 3 trial did not show a significant signal for increased periodontal disease risk with brensocatib.¹ Metersky said the drug's distinctive tolerability profile, including hyperkeratosis and periodontal changes, has not deterred patients from starting or continuing therapy in his practice.

He recalled one patient who asked if her teeth would fall out before starting treatment.

"That's not been an issue patients fear," said Metersky. "In truth, we didn't really see a significant signal for increased risk of periodontal disease in the phase 3 study."

He advises patients to brush twice daily, floss, and see their dentist regularly, noting any periodontal changes would likely develop slowly and be caught early. Metersky said he has also observed skin thickening and sloughing, most often behind the knees, elbows, feet, and hands, in one patient, but described the finding as uncommon in his experience.

The 1-year mark followed the American College of Chest Physicians' first North American clinical practice guideline for adult bronchiectasis, published in 2026, which includes long-term brensocatib among 13 conditional recommendations for patients with frequent exacerbations.³ Even with an approved therapy and dedicated guideline, unmet needs such as chronic cough, sputum burden, and disease progression persist across the bronchiectasis population.⁴

Watch the accompanying dynamic feature here: 

One Year Later: How Brensocatib Has Changed Bronchiectasis Care

Chalmers JD, et al. Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. 

FDA approves first bronchiectasis therapy, brensocatib, for ages 12 and up. HCPLive. Published August 12, 2025. Accessed August 21, 2026. 

https://www.hcplive.com/view/fda-approves-first-bronchiectasis-therapy-brensocatib-12-up

CHEST guideline 2026: 13 recommendations for non-CF bronchiectasis. HCPLive. Accessed August 21, 2026. 

https://www.hcplive.com/view/chest-guideline-2026-13-recommendations-bronchiectasis

Metersky M, Basavaraj A, Johnson V. One year later: how brensocatib has changed bronchiectasis care. HCPLive. Accessed August 21, 2026. 

https://www.hcplive.com/view/one-year-later-how-brensocatib-has-changed-bronchiectasis-care

One year after FDA approval, Mark Metersky, MD, discusses which bronchiectasis patients benefit most from brensocatib and its safety profile.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonary Fibrosis

Brensocatib Patient Selection Evolves 1 Year After FDA Approval

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.Each week, we highlight 5 key developments or headlines from healthcare that you need to know — whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine.

This week's top stories include the US Food and Drug Administration (FDA) approval of an autoinjector formulation of lerodalcibep-liga (Lerochol) and an updated indication statement for MACE reduction, topline phase 3 data for avexitide in adults with post-bariatric 

 following Roux-en-Y gastric bypass surgery, the FDA’s acceptance of a New Drug Application (NDA) for ecopipam (EBS-101) in pediatric Tourette syndrome, the accelerated approval of pariglasgene brecaparvovec-opnr (Genglycos) for glycogen storage disease type Ia (GSD1a), and the FDA’s Fast Track designation of LTI-03 for 

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of August 16, 2026 — let's jump in!

Lerodalcibep Autoinjector Receives FDA Approval for Hypercholesterolemia

On August 17, 2026, the FDA approved an autoinjector formulation of LIB Therapeutics’ lerodalcibep-liga (Lerochol), a third-generation PCSK9 inhibitor. The single-use device delivers the existing once-monthly, 300 mg/1.2 mL dose via a pressure-activated, single-motion injection completed in seconds.

The Agency also approved an updated indication statement for lerodalcibep-liga reflecting the established reduction in major adverse cardiovascular events (MACE) achieved through LDL-C lowering in adults with hypercholesterolemia treated with statins or with monoclonal antibody PCSK9 inhibitors added to statin therapy.

Avexitide Reduces Hypoglycemic Events in Phase 3 LUCIDITY Trial for PBH

On August 18, 2026, Amylyx Pharmaceuticals announced positive topline results from the phase 3 LUCIDITY trial evaluating avexitide in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass (RYGB) surgery.The trial met its primary endpoint as agreed with the FDA, with the investigational glucagon-like peptide-1 (GLP-1) receptor antagonist reducing the composite rate of Level 2 and Level 3 hypoglycemic events by 55% compared with placebo (

 = .000003). LUCIDITY also met all secondary endpoints.

FDA Accepts NDA for Ecopipam in Pediatric Tourette Syndrome

On August 19, 2026, the FDA accepted Teva Pharmaceuticals' NDA for ecopipam (EBS-101), a first-in-class selective D1 receptor antagonist, and granted Priority Review for the treatment of pediatric patients with Tourette syndrome, with a target action date late in the first quarter of 2027.

"If approved, ecopipam would be the first new therapy for Tourette syndrome in more than 10 years and the first novel mechanism of action in more than 50 years, offering patients and families a long-awaited new treatment option,” Eric Hughes, MD, PhD, executive vice president, Global R&D and chief medical officer, at Teva, said in a statement.

FDA Approves Gene Therapy for Glycogen Storage Disease Type 1a

On August 20, 2026, the FDA granted accelerated approval to pariglasgene brecaparvovec-opnr (Genglycos), a one-time AAV8 gene therapy, to reduce daily cornstarch intake as an adjunct to nutritional management in patients 8 years and older with GSD1a, making it the first approved treatment for the condition.

FDA Fast Tracks LTI-03 for Idiopathic Pulmonary Fibrosis

On August 20, 2026, the FDA granted Fast Track designation to LTI-03, an inhaled peptide therapy from Rein Therapeutics, for IPF. The decision follows a prior Orphan Drug designation already granted to LTI-03 for IPF, whose Caveolin-1-derived mechanism sets it apart from existing antifibrotics by targeting alveolar epithelial repair alongside fibrotic signaling.

Multiple FDA actions and late-stage readouts spanned cardiometabolic, neurologic, rare genetic, and pulmonary disease programs. Lerodalcibep-liga gained an autoinjector option for monthly PCSK9 inhibition and an updated MACE-reduction indication tied to LDL-C lowering. Avexitide achieved a highly significant 55% reduction in clinically meaningful hypoglycemic events in phase 3 post–Roux-en-Y post-bariatric hypoglycemia. Ecopipam’s pediatric Tourette NDA was accepted with Priority Review. AAV8 gene therapy pariglasgene brecaparvovec-opnr received accelerated approval for GSD1a. LTI-03 secured Fast Track for IPF.

Stay updated with the latest healthcare breakthroughs, including a new lerodalcibep FDA approval and phase 3 avexitide data in post-bariatric hypoglycemia.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


The HCPFive: Top News for Healthcare Providers from the Week of 08/16

Daniel Taylor-Sweet, PhD | Image Credit: LinkedIn

 screening strategy has identified a substantial proportion of patients living with diabetes with unrecognized symptomatic HF, highlighting the need for further adoption of similar screening techniques.

HF is a frequent complication in patients with diabetes. Risk is elevated even after controlling risk factors like hypertension, hypercholesterolemia, hyperglycemia, and albuminuria. Additionally, the increasing incidence of 

 is expected to increase the incidence of HF. However, guidelines for HF treatment do not consistently include biomarker-based screening, and it is rarely performed in clinical practice.

“To address this knowledge gap, we conducted a randomized controlled trial evaluating the diagnostic yield of a systematic natriuretic peptide-guided screening strategy to detect unrecognized symptomatic HF in adults with diabetes and additional risk factors for HF,” Daniel Taylor-Sweet, PhD, clinical fellow at NHS Golden Jubilee and research fellow at the University of Glasgow, and colleagues wrote.

TARTAN-HF was a prospective, multicenter, unblinded, randomized controlled trial, one of several in the broader SYMPHONY program. This program aimed to examine the potential benefits of HF screening in a variety of populations. TARTAN-HF enrolled patients ≥40 years of age with an established diagnosis of 

 or T2D and ≥1 additional risk factor for HF. These risk factors included coronary artery disease, previous ischemic or embolic stroke, peripheral artery disease, or chronic obstructive pulmonary disease, among other factors.

Prior to randomization, medical and drug history were recorded, and patients were invited to complete the Kansas City Cardiomyopathy Questionnaire (KCC-12) and the EuroQol 5-Dimension 3-Level questionnaire. Eligible patients were then randomly assigned in a 1:1 ratio to either screening or usual care for HF, after which they were invited to an in-person study visit during which investigators measured NT-proBNP, sampled peripheral venous blood for hematology and biochemistry, sampled urine for urinary albumin-to-creatinine ratio, and a 12-lead electrocardiograph.

The trial’s primary endpoint was a diagnosis of HF at 6 months after randomization. This was defined as the presence of each of the following 3 criteria: signs and/or symptoms of HF, an elevated NT-proBNP concentration ≥125 pg/mL, and ≥1 echocardiographic structural or functional abnormality consistent with adverse cardiac remodeling or elevated filling pressures. These diagnoses were classified according to ejection fraction phenotype.

A total of 706 patients were randomized between January 2023 and May 2025, with 354 assigned to screening and 352 to usual care. Median age was 71 years, and 90% of patients had T2D. Median duration of diabetes was 12.5 years. 72% of patients had their diabetes managed in primary care, while the remainder were attending a secondary care diabetes clinic. The most common risk factors were chronic kidney disease (57%) and coronary artery disease (39%).

Among the patients assigned to screening, an HF diagnosis was ultimately made in 87 (24.6%). A diagnosis of HF with reduced ejection fraction (HFrEF) was made in 3 patients, HF with mildly reduced ejection fraction (HFmrEF) was made in 3 patients, and HF with preserved ejection fraction (HFpEF) in 81 patients (23%). No further diagnoses were made in the 6 months following randomization outside of the screening process. However, the usual care group only saw 2 diagnoses (odds ratio [OR], 58; 95% CI, 14-236; 

Ultimately, Taylor-Sweet and colleagues concluded that NT-proBNP-based screening is an effective method for improving HF diagnosis among patients who would otherwise have gone unrecognized. The team encourages further adoption of this and similar screening strategies to combat HF.

“The high diagnostic yield of the proposed screening strategy strengthens the case for the consideration of the implementation of natriuretic peptide-based screening for undiagnosed symptomatic HF in high-risk people with diabetes,” Taylor-Sweet and colleagues wrote.

Taylor-Sweet, D, Petrie, M, McKinley, G. et al. Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF). 

https://doi.org/10.1016/j.jacc.2026.06.042

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. 

https://academic.oup.com/eurheartj/article/42/36/3599/6358045

Systematic natriuretic peptide–guided screening using NT-proBNP in high-risk adults with diabetes uncovered a large burden of previously unrecognized symptomatic heart failure, predominantly HFpEF. In a prospective, multicenter randomized trial of older patients with long-standing diabetes and added cardiovascular comorbidity, screening markedly increased 6‑month HF diagnoses versus usual care, which detected very few cases. Diagnostic criteria required symptoms/signs, NT-proBNP ≥125 pg/mL, and supportive echocardiographic abnormalities. Findings support broader implementation of biomarker-based HF screening in diabetology care pathways.

A recent study has shown that a significantly greater proportion of patients with HF were correctly identified when testing NT-proBNP levels.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Type 1 Diabetes

NT-proBNP Sampling May Improve Heart Failure Screening in Patients With Diabetes

This segment of The Medical Sisterhood podcast highlights setting boundaries in mentorship and the pressure of representation for women of color in medicine.

How Women of Color in Medicine Navigate Representation Pressure

Carotid ultrasound data reveal early arterial injury even at earlier CKM stages, says Donald Lloyd-Jones, MD, MS

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

4 Out of 5 Young Adults Show Early Cardiovascular-Kidney-Metabolic Risk

Manish Wadhwa, MD, is a cardiologist and electrophysiologist with San Diego Arrhythmia Associates and the chief executive officer of SummaCor.

Manish Wadhwa, MD, discusses Implicity’s newest algorithm to improve the accuracy of implantable cardiac monitors in identifying arrhythmic episodes.

Arrhythmia

FDA News

FDA-Cleared, AI-Assisted ECG Analyzer Algorithm Reduces False Positives in ICMs

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Pamufetinib 50 mg and 100 mg did not slow FVC decline versus continued nintedanib or pirfenidone in progressive fibrosing ILD, a phase 2b trial found.

Pamufetinib Fails to Slow FVC Decline in Progressive Fibrosing ILD

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD

Melinda Gooderham, MD, is a dermatologist and the medical director at the SKiN Centre for Dermatology.

This Q&A interview continues Gooderham's discussion of new upadacitinib treatment data on patients living with severe alopecia areata.

Alopecia

Q&A: Upadacitinib Drives Eyebrow, Eyelash Regrowth with Consistent Safety

Andrew Mastro, MS, PA-C, closes out this stretch of the conversation by asking Alexa Hetzel, MS, PA-C, to look three to five years ahead and describe how she expects the plaque psoriasis treatment paradigm to evolve.

The Future of Plaque Psoriasis Treatment Over the Next 3 to 5 Years

Andrew Mastro, MS, PA-C, widens the lens and asks Alexa Hetzel, MS, PA-C, where icotrokinra sits within the broader plaque psoriasis landscape, including whether route of administration itself shapes patient preference.

Positioning Icotrokinra as First-Line Therapy for Plaque Psoriasis

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

PAH specialists discuss upfront combination therapy and the disconnect between guidelines and community practice.

PAH in Community Practice: Algorithms and Access

Genetic variants tied to CAR T toxicity and expansion could guide how researchers screen healthy donors for allogeneic CAR T products.

Latest News

Why Mentorship Matters Most for Dermatology Trainees

CKM Syndrome, Artery Damage Prevalence Higher in Young Adults than Previously Believed

Brensocatib Patient Selection Evolves 1 Year After FDA Approval

The HCPFive: Top News for Healthcare Providers from the Week of 08/16

NT-proBNP Sampling May Improve Heart Failure Screening in Patients With Diabetes